Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month

Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a ​30-day supply of their newly approved rare disease drug, ‌Lisraya.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。